4-Brom-2-ethylfuran | 3439-01-8

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 芳基卤化物
• 英文名称: 4-Brom-2-ethylfuran
• 英文别名: 2-Ethyl-4-bromofuran；4-bromo-2-ethylfuran
• CAS: 3439-01-8
• 化学式: C₆H₇BrO
• 分子量: 175.025
• InChiKey: IRZLHHVOEATNFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-bromo-5-ethylfuran 在 potassium tert-butylate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 以60%的产率得到4-Brom-2-ethylfuran
  参考文献：
  名称：

  Efficient procedure for the preparation of 2-bromo-5-ethylfuran and its unexpected isomerization

  摘要：

  DOI：

  10.1134/s107042801409022x

文献信息

• [EN] EZH2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS D'EZH2 ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016073956A1

  公开（公告）日：2016-05-12

  The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1and/or EZH2 inhibitors.

  本公开提供了任一式（I）和（II）中的化合物。本文描述的化合物是组蛋白甲基转移酶抑制剂（例如增强子齿同源蛋白1（EZH1）和增强子齿同源蛋白2（EZH2）），可用于治疗和/或预防广泛范围的疾病（例如增生性疾病）。本公开还提供了包括或使用本文描述的化合物的药物组合物、试剂盒、方法和用途。本公开还提供了识别EZH1和/或EZH2抑制剂的方法。
• [EN] DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE DIHYDROPTÉRIDINONE ET LEURS UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2016022970A1

  公开（公告）日：2016-02-11

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.